Assertio Therapeutics is a drug manufacturers - specialty & generic business based in the US. Assertio Therapeutics shares (ASRT.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $0.78 – a decrease of 1.97% over the previous day. Assertio Therapeutics employs 53 staff and has a trailing 12-month revenue of around $152.1 million.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, Assertio Therapeutics's shares have ranged in value from as little as $0.77 up to $8.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio Therapeutics's is 0.965. This would suggest that Assertio Therapeutics's shares are less volatile than average (for this exchange).
Historical closes compared with the last close of $0.78
| 1 week (2024-04-11) | -10.16% |
|---|---|
| 1 month (2024-03-18) | -22.77% |
| 3 months (2024-01-18) | -7.36% |
| 6 months (2023-10-18) | -65.64% |
| 1 year (2023-04-18) | -87.09% |
| 2 years (2022-04-18) | -71.84% |
| 3 years (2021-04-18) | 62.06% |
| 5 years (2019-04-17) | -81.82% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Assertio Therapeutics P/E ratio, PEG ratio and EBITDA
Assertio Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Assertio Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Assertio Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $53.2 million.
The EBITDA is a measure of a Assertio Therapeutics's overall financial performance and is widely used to measure a its profitability.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
We analyze robo-advisors across 7 key metrics to see how they compare.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Features and fees to consider before you open an account with this trading platform.
SoFi is a commission-free platform with both active and automated investment accounts.
What you need to know about investing in the leading indicator for the overall US stock market.
Take advantage of $0 trades and no investment minimums with this well-known broker.
A deep dive into the highlights and limitations of Robinhood.